Disc Medicine (IRON) Net Equity Issued and Repurchased (2020 - 2023)
Disc Medicine (IRON) posted quarterly Net Equity Issued and Repurchased of -$20.0 million for Q4 2023, down 158.45% quarter-over-quarter from $34.2 million in Q1 2023.
Powered by 
Analysis
Disc Medicine (IRON) Net Equity Issued and Repurchased (2020 - 2023) Analysis & Trends
Disc Medicine (IRON) has reported Net Equity Issued and Repurchased for 2 consecutive years, with -$20.0 million the latest figure, recorded in Q4 2023.
- In Q4 2023, Net Equity Issued and Repurchased changed N/A year-over-year to -$20.0 million; the TTM figure through Dec 2023 stood at $14.2 million (changed N/A YoY), while the FY2022 annual figure was $53.5 million, down 40.46% from the prior year.
- Net Equity Issued and Repurchased declined to -$20.0 million in Q4 2023 per IRON's latest filing, from $34.2 million in the prior quarter.
- Across five years, Net Equity Issued and Repurchased topped out at $34.2 million in Q1 2023 and bottomed at -$20.0 million in Q4 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 49.20 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 141.90 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Disc Medicine | 3.06 Bn | 3.06 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2023 | -20.00 Mn |
| Mar 31, 2023 | 34.22 Mn |
| Dec 31, 2020 | 25,000.00 |
| Sep 30, 2020 | 25,000.00 |
| Mar 31, 2020 | 20.08 Mn |